The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines
Ruben Rose, Franziska Neumann, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher, View ORCID ProfileAndi Krumbholz
doi: https://doi.org/10.1101/2021.07.09.21260251
Ruben Rose
1Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
Franziska Neumann
2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
Olaf Grobe
2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
Thomas Lorentz
2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
Helmut Fickenscher
1Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
Andi Krumbholz
1Institut für Infektionsmedizin, Christian-Albrechts-Universität zu Kiel und Universitätsklinikum Schleswig Holstein, Campus Kiel, Brunswiker Straße 4, D-24105 Kiel, Germany
2Labor Dr. Krause und Kollegen MVZ GmbH, Steenbeker Weg 23, D-24106 Kiel, Germany
Article usage
Posted September 02, 2021.
The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines
Ruben Rose, Franziska Neumann, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher, Andi Krumbholz
medRxiv 2021.07.09.21260251; doi: https://doi.org/10.1101/2021.07.09.21260251
The anti-SARS-CoV-2 immunoglobulin G levels and neutralising capacities against alpha and delta virus variants of concern achieved after initial immunisation with vector vaccine followed by mRNA vaccine boost are comparable to those after double immunisation with mRNA vaccines
Ruben Rose, Franziska Neumann, Olaf Grobe, Thomas Lorentz, Helmut Fickenscher, Andi Krumbholz
medRxiv 2021.07.09.21260251; doi: https://doi.org/10.1101/2021.07.09.21260251
Subject Area
Subject Areas
- Addiction Medicine (371)
- Allergy and Immunology (689)
- Anesthesia (184)
- Cardiovascular Medicine (2754)
- Dermatology (235)
- Emergency Medicine (414)
- Epidemiology (12403)
- Forensic Medicine (10)
- Gastroenterology (784)
- Genetic and Genomic Medicine (4261)
- Geriatric Medicine (396)
- Health Economics (699)
- Health Informatics (2758)
- Health Policy (1019)
- Hematology (369)
- HIV/AIDS (880)
- Medical Education (404)
- Medical Ethics (112)
- Nephrology (453)
- Neurology (4043)
- Nursing (216)
- Nutrition (599)
- Oncology (2128)
- Ophthalmology (604)
- Orthopedics (251)
- Otolaryngology (313)
- Pain Medicine (256)
- Palliative Medicine (77)
- Pathology (478)
- Pediatrics (1149)
- Primary Care Research (470)
- Public and Global Health (6653)
- Radiology and Imaging (1446)
- Respiratory Medicine (886)
- Rheumatology (421)
- Sports Medicine (353)
- Surgery (464)
- Toxicology (57)
- Transplantation (192)
- Urology (171)